Lv11
50 积分 2024-04-09 加入
A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL
30分钟前
已关闭
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome
1个月前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
2个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
8个月前
已完结
Causal Assessment of Phenotypic Risk Factors with Keratinocyte Carcinoma
9个月前
已完结
Number needed to test: quantifying risk stratification provided by diagnostic tests and risk predictions
9个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
1年前
已完结
Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations
1年前
已关闭
Abrogation of USP9X Is a Potential Strategy to Decrease PEG10 Levels and Impede Tumor Progression in Cutaneous T-Cell Lymphoma
1年前
已完结
皖公网安备34019202002308
